Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Cite this paper

@article{Krishnan2011AutologousHS, title={Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.}, author={Amrita Y. Krishnan and Marcelo C. Pasquini and Brent R Logan and Edward A. Stadtmauer and David H. Vesole and Edwin P Alyea and Joseph H Antin and Raymond L. Comenzo and Stacey Goodman and Parameswaran N. Hari and Ginna G. Laport and Muzaffar H Qazilbash and Scott Rowley and Firoozeh Sahebi and George Somlo and Dan T. Vogl and Daniel Weisdorf and Marian G Ewell and Juan Wu and Nancy L. Geller and Mary Horowitz and S. Giralt and David G Maloney}, journal={The Lancet. Oncology}, year={2011}, volume={12 13}, pages={1195-203} }